Johnson & Johnson holds a concentrated book of 15 stocks worth $798.7M as of Q2 2026 (disclosed Aug 6, 2026, a ~37-day 13F lag). This quarter they opened Cerebras Systems Inc - A. Their largest long position is Protagonist Therapeutics Inc at 38% of the equity book. Cloning the disclosed picks since 2026 would be +41% (+117.9%/yr). That is a simulation of the disclosed long book, not audited returns.
The reported book (valued from quarter-end) returned +61.9%, a 20.7-point gap that is the cost of the ~37-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Johnson & Johnson's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~37 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
73% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Johnson & Johnson
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 16 / 15 | $603.2M |
| GEODE CAPITAL MANAGEMENT, LLC | 16 / 15 | $472.8M |
| MORGAN STANLEY | 16 / 15 | $191.5M |
| BNP PARIBAS FINANCIAL MARKETS | 16 / 15 | $33.9M |
| Tower Research Capital LLC (TRC) | 16 / 15 | $1.0M |
| BlackRock, Inc. | 15 / 15 | $1.6B |
| STATE STREET CORP | 15 / 15 | $683.0M |
| JPMORGAN CHASE & CO | 15 / 15 | $33.0M |
Ranked by how many of Johnson & Johnson's top 15 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Protagonist Therapeutics Inc COM | $300.2M | 2.45M | 37.6% | —Held | |
| 2 | Nanobiotix SPONSORED ADS | $212.0M | 5.62M | 26.5% | —Held | |
| 3 | Meiragtx Hldgs PLC COM | $89.7M | 6.64M | 11.2% | —Held | |
| 4 | Rapport Therapeutics Inc COM | $74.4M | 1.78M | 9.3% | —Held | |
| 5 | Contineum Therapeutics Inc CL A | $32.4M | 1.98M | 4.1% | —Held | |
| 6 | Legend Biotech Corp SPONSORED ADS | $23.5M | 814.6K | 2.9% | —Held | |
| 7 | CVRX Inc COM | $20.7M | 4.02M | 2.6% | —Held | |
| 8 | Xencor Inc COM | $12.0M | 748.1K | 1.5% | —Held | |
| 9 | Cerebras Systems Inc COM CL A | $11.8M | 53.6K | 1.5% | ▲New New position | |
| 10 | Fate Therapeutics Inc COM | $9.1M | 3.38M | 1.1% | —Held | |
| 11 | Procept Biorobotics Corp COM | $8.1M | 357.9K | 1.0% | —Held | |
| 12 | Neumora Therapeutics Inc. COM | $3.1M | 1.85M | 0.4% | —Held | |
| 13 | Vor Biopharma Inc COM NEW | $989K | 53.7K | 0.1% | —Held | |
| 14 | Standard Biotools Inc COM | $257K | 312.0K | 0.0% | —Held | |
| 15 | Adicet Bio Inc COM NEW | $197K | 22.8K | 0.0% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/200406/holdings"
Use Arkolith to show JOHNSON & JOHNSON's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.